anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a multicenter, prospective, randomized controlled study which aims at evaluating the efficacy of different doses of IVIG (intravenous immunoglobulin) in the treatment of patients with severe HFRS(hemorrhagic fever with renal syndrome), and providing reference for the future application of IVIG in severe hemorrhagic fever with renal syndrome. This study will include approximately 100 patients with severe hemorrhagic fever with renal syndrome who are randomly assigned to either the IVIG 10g/d group or the IVIG 20g/d group in a 1:1 ratio. The participants in each group will receive treatments for 6 days. Both groups are given routine liquid therapy and symptomatic supportive treatment. The main endpoints include transformation rate, post-period rate, mortality rate, and duration of the disease. Secondary endpoints include the incidence of complications and length of hospital stay.
The gut microbiota has been reported to be perturbed by chemotherapeutic agents and to modulate side effects. However, the critical role of β-hydroxybutyrate (BHB) in the regulation of the gut microbiota and the pathogenesis of chemotherapeutic agents related nephrotoxicity remains unknown. We conducted a comparative analysis of the composition and function of gut microbiota in healthy, cisplatin-challenged, BHB-treated, and high-fat diet-treated mice using 16 S rDNA gene sequencing. To understand the crucial involvement of intestinal flora in BHB's regulation of cisplatin -induced nephrotoxicity, we administered antibiotics to deplete the gut microbiota and performed fecal microbiota transplantation (FMT) before cisplatin administration. 16 S rDNA gene sequencing analysis demonstrated that both endogenous and exogenous BHB restored gut microbiota dysbiosis and cisplatin-induced intestinal barrier disruption in mice. Additionally, our findings suggested that the LPS/TLR4/NF-κB pathway was responsible for triggering renal inflammation in the gut-kidney axis. Furthermore, the ablation of the gut microbiota ablation using antibiotics eliminated the renoprotective effects of BHB against cisplatin-induced acute kidney injury. FMT also confirmed that administration of BHB-treated gut microbiota provided protection against cisplatin-induced nephrotoxicity. This study elucidated the mechanism by which BHB affects the gut microbiota mediation of cisplatin-induced nephrotoxicity by inhibiting the inflammatory response, which may help develop novel therapeutic approaches that target the composition of the microbiota.
BACKGROUND/OBJECTIVES: This study aims to evaluate the potential of the SarQoL questionnaire as a screening tool for sarcopenic obesity by comparing its effectiveness in Spanish and Belgian community-dwelling older people. This research seeks to address the primary question of whether the SarQoL can reliably differentiate quality of life impacts between these groups.
METHODS: A cross-sectional study was conducted involving community-dwelling older adults from Valencia (Spain) and Liège (Belgium). Participants were assessed using the SarQoL questionnaire, which measures health-related quality of life specifically for sarcopenia, and a sarcopenic obesity diagnostic method based on a combination of the EWGSOP2 criteria for sarcopenia and of body mass index for obesity. The sample included diverse demographic and clinical characteristics to ensure comprehensive analysis. Statistical methods were employed to compare the outcomes between the two populations.
RESULTS: The study highlighted a significant relationship between quality-of-life scores and the prevalence of sarcopenic obesity in the Spanish and Belgian populations. The SarQoL questionnaire effectively identified lower quality of life in individuals with sarcopenic obesity, demonstrating its potential as a reliable screening tool across different populations. In conclusion, the SarQoL questionnaire proved to be an effective tool for evaluating quality of life and for screening individuals with sarcopenic obesity.
CONCLUSIONS: Future research should prioritize longitudinal studies to determine the SarQoL questionnaire's predictive value and investigate interventions to alleviate the adverse effects of sarcopenic obesity. Our results highlight the critical need to include quality of life assessments in managing sarcopenic obesity, advocating for a comprehensive approach to patient care.
Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
A composition comprising a nanoparticle, wherein the nanoparticle comprises a polymer/copolymer conjugated to a moiety is disclosed. A method of forming a nanostructure includes stirring poly(lactide-co-glycolide (PLGA) and 11-Ethyl-3-(dimethylaminopropyl) carbodiimide (EDC) in CH 2 Cl 2  to create a PLGA mixture, n-boc-ethyelenediamine and N,N-Diisopropylethylamine (DIEA) are added to the PLGA mixture to create a reaction mixture. The reaction mixture is then precipitated in cold diethyl ether to form a purified polymer, which is then dried. The dried and purified polymer is then reconstituted in CH 2 Cl 2 :TFA solution and stirred under inert conditions. The product of the reconstituting step is evaporated to form a clear viscous residue that is dissolved in CH 2 Cl 2  and then precipitated in cold ether to form a polymer. These functional polymers can encapsulate a variety of bioactives forming nanosystems improving the performance of bioactives.
Pain and itch are regulated by a diverse array of neuropeptides and their receptors in superficial laminae of the spinal cord dorsal horn (DH). Neuropeptide Y (NPY) is normally expressed on DH neurons but not sensory neurons. By contrast, the Npy2r receptor (Y2) is expressed on the central and peripheral terminals of sensory neurons but not on DH neurons. Neurophysiological slice recordings indicate that Y2-selective agonists inhibits spinal neurotransmitter release from sensory neurons. However, behavioral pharmacology studies indicate that Y2 agonists exert minimal changes in nociception, even after injury. Additional discrepancies in the behavioral actions of the Y2-antagonist BIIE0246 - reports of either pronociception or antinociception - have now been resolved. In the normal state, spinally-directed (intrathecal) administration of BIIE0246 elicits ongoing nociception, hypersensitivity to sensory stimulation, and aversion. Conversely, in the setting of nerve injury and inflammation, intrathecal BIIE024 reduced not only mechanical and thermal hypersensitivity, but also a measure of the affective dimension of pain (conditioned place preference). When administered in chronic pain models of latent sensitization, BIIE0246 produced a profound reinstatement of pain-like behaviors. We propose that tissue or nerve injury induces a G protein switch in the action of NPY-Y2 signaling from antinociception in the naïve state to the inhibition of mechanical and heat hyperalgesia in the injured state, and then a switch back to antinociception to keep LS in a state of remission. This model clarifies the pharmacotherapeutic potential of Y2 research, pointing to the development of a new non-opioid pharmacotherapy for chronic pain using Y2 antagonists in patients who do not develop LS.
TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
A hair dyeing process for improved and milder dyeing of hair, especially human hair. The ready-to-use dyeing composition comprises carboxylic acids in addition to dyeing agents and oxidizing agents in order to improve dyeing efficiency with less loss of natural hair properties. A process comprises applying onto hair a ready-to-use composition obtained by mixing compositions A comprising one or more hair dyes and one or more alkalising agents and having a pH of 7.5 to 12, B being an aqueous composition comprising one or more oxidising agents and having a pH of 1.5 to 5 and C comprising (i) one or more carboxylic acids or salts thereof having 3 or more carboxyl groups and (ii) one or more additional organic acids and/or salts thereof having one or two carboxyl groups. Composition C comprises (i) and (ii) at a concentration of 10 to 100% by weight. The ready-to-use composition has a pH of 8 to 11, comprises (i) and (ii) at a concentration of 1 to 10% by weight and is prepared by mixing A, B and C in a weight ratio in the range of 1:2:0.2 to 1:1:1. A kit for hair comprises compositions A, B and C.
This study aims to refine our understanding of the inherent heterogeneity in cervical cancer by exploring differential gene expression profiles, immune cell infiltration dynamics, and implicated signaling pathways in the two predominant histological types of cervix carcinoma, Squamous Cell Carcinoma (SCC) and Adenocarcinoma (ADC). Targeted gene expression data that were previously generated from samples of primary cervical cancer were re-analyzed. The samples were grouped based on their histopathology, comparing SCC to ADC. Each tumor in the study was confirmed to be high risk human papilloma virus (hrHPV) positive. A total of 21 cervical cancer samples were included, with 11 cases of SCC and 10 of ADC. Data analysis revealed a total of 26 differentially expressed genes, with 19 genes being overexpressed in SCC compared to ADC (Benjamini-Hochberg (BH)-adjusted p-value < 0.05). Importantly, the immune checkpoint markers CD274 and CTLA4 demonstrated significantly higher expression in SCC compared to ADC. In addition, SCC showed a higher infiltration of immune cells, including B and T cells, and cytotoxic cells. Higher activation of a variety of pathways was found in SCC samples including cytotoxicity, interferon signaling, metabolic stress, lymphoid compartment, hypoxia, PI3k-AKT, hedgehog signaling and Notch signaling pathways. Our findings show distinctive gene expression patterns, signaling pathway activations, and trends in immune cell infiltration between SCC and ADC in cervical cancer. This study underscores the heterogeneity within primary cervical cancer, emphasizing the potential benefits of subdividing these tumours based on histological and molecular differences.
INTRODUCTION: Unfractionated heparin is a widely used anticoagulant in critically ill patients. It has a well-established safety profile and remains an attractive option for clinicians due to its short half-life and reversibility. Heparin has a unique pharmacokinetic profile, which contributes to significant inter-patient and intra-patient variability in effect. The variability in anticoagulant effect combined with heparin's short half-life mean close monitoring is required for clinical efficacy and preventing adverse effects. To optimize heparin use in critically ill patients, effective monitoring assays and dose adjustment strategies are needed.
AREAS COVERED: This paper explores the use of heparin as an anticoagulant and optimal approaches to monitoring in critically ill patients.
EXPERT OPINION: Conventional monitoring assays for heparin dosing have significant limitations. Emerging data appear to favor using anti-Xa assay monitoring for heparin anticoagulation, which many centers have successfully adopted as the standard. The anti-Xa assay appears have important benefits relative to the aPTT for heparin monitoring in critically ill patients, and should be considered for broader use.
BACKGROUND: Intestinal inflammation has various causes and leads to some inflammatory diseases, of which autophagy pathway dysfunction could be considered as one of them. Probiotics could have a positive effect on reducing inflammation by activating the autophagy pathway. To evaluate the precise effects of probiotics as preventive and therapeutic agents to control the symptoms of inflammatory diseases, we aimed to investigate the efficacy of Lactobacillus spp. in regulating the autophagy signaling pathway.
METHODS: A quantitative real-time polymerase chain reaction assay was used to analyze the expression of autophagy genes involved in the formation of phagophores, autophagosomes, and autolysosomes after exposing the HT-29 cell line to sonicated pathogens and adding Lactobacillus spp. before, after, and simultaneously with inflammation. A cytokine assay was also accomplished to evaluate the interleukin (IL)-6 and IL-1β level following the probiotic treatment.
RESULTS: Lactobacillus spp. generally increased autophagy gene expression and consumption of Lactobacillus spp. before, simultaneously, and after inflammation, ultimately leading to activate autophagy pathways. The proinflammatory cytokines including IL-6 and IL-1β decreased after probiotic treatment.
CONCLUSIONS: Our native probiotic Lactobacillus spp. showed beneficial effects on HT-29 cells by increasing autophagy gene expression and decreasing the proinflammatory cytokines production in all treatments. Therefore, this novel probiotic cocktail Lactobacillus spp. can prevent and treat inflammation-related diseases.
A thick layer of lidocaine and prilocaine cream is applied to intact skin and covered with an occlusive dressing (see INSTRUCTIONS FOR APPLICATION).

Minor Dermal Procedures: For minor procedures such as intravenous cannulation and venipuncture, apply 2.5 grams of lidocaine and prilocaine cream (1/2 the 5 g tube) over 20 to 25 cm2 of skin surface for at least 1 hour. In controlled clinical trials using lidocaine and prilocaine cream, two sites were usually prepared in case there was a technical problem with cannulation or venipuncture at the first site.

Major Dermal Procedures: For more painful dermatological procedures involving a larger skin area such as split thickness skin graft harvesting, apply 2 grams of lidocaine and prilocaine cream per 10 cm2 of skin and allow to remain in contact with the skin for at least 2 hours.

Adult Male Genital Skin: As an adjunct prior to local anesthetic infiltration, apply a thick layer of lidocaine and prilocaine cream (1 g/10 cm2 ) to the skin surface for 15 minutes. Local anesthetic infiltration should be performed immediately after removal of lidocaine and prilocaine cream.

Dermal analgesia can be expected to increase for up to 3 hours under occlusive dressing and persist for 1 to 2 hours after removal of the cream. The amount of lidocaine and prilocaine absorbed during the period of application can be estimated from the information in Table 2, ** footnote, in Individualization of Dose.
Patients would receive autologous CAR-T cell therapy targeting both CD19 and CD22. The dosage for CD19-CAR-T cell was 2×10e6/kg and CD22-CAR-T cell was 1×10e6/kg. Both CAR-T cells were infused at the same day.
FIELD: organic chemistry. SUBSTANCE: product: 2-methyl-3-trifluoromethylaniline of the formula (I). Method involves the following reactions: compound of the formula (II)where Z - halide is subjected for methylation and methylation product obtained of the formula (III)where Z has a value indicated above is subjected for reduction followed by acid hydrolysis of compound of the formula (IV)or acid hydrolysis followed by reduction of compound of the formula (V)where Z - as indicated above; or compound of the formula (VI)is methylated and methylation product obtained of the formula (IV)is subjected for acid hydrolysis if necessary after preliminary isolation of product of the formula (IV), or compound of the formula (IV)is subjected for hydrolysis with hydrogen bromide. Other object of invention are derivatives of trifluoromethylpivalanilide of the general formula (VII)where Y means hydrogen or halide which are intermediate products for synthesis of 2-methyl-3-trifluoromethylaniline. These derivatives were synthesized by methylation of compound of the formula (VIII)where Y - as indicated above. EFFECT: improved method of synthesis.
A coaxial implant has been developed using entirely biodegradable polymeric materials. As referred to herein, a coaxial implant is a device having a core containing drug, surrounded by a semi-permeable membrane that controls the rate of release from the core. The device is formed by extrusion, using a pre-milling and extruding step to maximize uniformity of drug dispersion within the polymeric material. In one embodiment, the polymer is processed to yield a semi-crystalline polymer, rather than an amorphous polymer. The core containing the drug and the polymer membrane(s) can be the same or different polymer. The polymer can be the same or different composition (i.e., both polycaprolactone, or both poly(lactide-co-glycolide) of different monomer ratios, or polycaprolactone outside of a core of poly(lactide)), of the same or different molecular weights, and of the same or different chemical structure (i.e., crystalline, semi-crystalline or amorphous). The core acts as a reservoir of drug, which partitions from the core polymer to form a saturated solution of at least 10% drug at the polymer membrane.
Each child will participate in a structured cognitive behavioral therapy program entitled "better manage your anger and frustration". 15 workshops is planned.
The parent-child interactive program is designed by three phase: precontemplation/ contemplation stage, preparation stage, and action/maintenance stage. In phase 1, the main focus is to promote motivation through information providing and being aware of children's perception toward ETS and smoking. In phase 2, the main focus is strengthening parents/children's ability to plan and implement smoke-free home. In phase 3, intervention focus is on maintaining behavioral change and smoke-free home by continuously strengthening implementing ability, identifying and eliminating barriers, and reinforcing successful experience. Parent-child interaction is designed through three phases, and parents perceive children's feedback through all phases.
PURPOSE: Provided is salt tolerant strain, Bacillus subtilisvar. chungkookjang (KTCT 0697BP) isolated from Korean traditional fermented food, chungkookjang. And poly-gamma-glutamic acid is also provided which is edible, water-soluble, anionic, biodegradable and produced from the strain, and which is used in cosmetics, absorbent, biodegradable plastic materials. CONSTITUTION: A Bacillus subtilisvar. chungkookjang (KTCT 0697BP) is isolated from chungkookjang. A preparation method of poly-gamma-glutamic acid from the strain comprises the steps of: (a) inoculating and cultivating Bacillus subtilisvar. chungkookjang (KTCT 0697BP) in a medium to produce poly-gamma-glutamic acid and then, adding acids until PH becomes 2 to 4 , to obtain liquid that includes poly-gamma-glutamic acid; (b) removing polysaccharide from the resultant liquid, followed by extracting with solvent and centrifuging it to obtain precipitate of poly-gamma-glutamic acid; (c) dissolving the precipitant by adding distilled water, then degrading exogenous protein by proteinase; and (d) dialyzing it to remove free glutamic acid and concentrating it.
The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain. The participants will complete an outcome assessment within 30 days of the last group session.
Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right. PCT could provide another treatment option that might be preferable to some Veterans and promote patient choice. Additionally, PCT would require less clinician training and specialization than ACT-MI. Using PCT as an active comparison condition will determine whether it is necessary to train clinicians in ACT-MI or if therapists with exposure to supportive problem-solving therapy approaches can lead a group that impacts functioning among Veterans reporting moral injury-related distress.
A pharmacokinetic study of ranolazine in subjects with severe renal impairment (CrCL <30 mL/min) was stopped when 2 of 4 subjects developed acute renal failure after receiving ranolazine extended-release tablets 500 mg twice daily for 5 days (lead-in phase) followed by 1000 mg twice a day (1 dose in one subject and 11 doses in the other). Increases in creatinine, BUN, and potassium were observed in 3 subjects during the 500 mg lead-in phase. One subject required hemodialysis, while the other 2 subjects improved upon drug discontinuation [see WARNINGS AND PRECAUTIONS (5.2)]. Monitor renal function periodically in patients with moderate to severe renal impairment. Discontinue ranolazine extended-release tablets if acute renal failure develops.

In a separate study, Cmax was increased between 40% and 50% in patients with mild, moderate, or severe renal impairment compared to patients with no renal impairment, suggesting a similar increase in exposure in patients with renal failure independent of the degree of impairment. The pharmacokinetics of ranolazine has not been assessed in patients on dialysis.
1. Technical Result Increase in efficiency of treatment of diseases characterized by matrix metalloproteinase.         2. Essence A compounds of the formula wherein R1-R8, and Ar are defined in the description; the mentioned compounds are useful in the treatment of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity; pharmaceutical compositions for treatment of such diseases at which it is reasonable inhibiting of matrix metalloproteinase and mammalian reprolysin comprises as an active ingredient the mentioned compound in pharmaceutically effective amount.          3. Field of Application Medicine.                Tables: 4